APGE•benzinga•
Why Is Apogee Therapeutics Stock Trading Higher On Monday?
Summary
Apogee's APG808 cut key asthma biomarker FeNO by 53% at 12 weeks with no severe adverse events, showing potential for long-term maintenance dosing.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 12, 2025 by benzinga